Use of Jianpi Jiedu Herbs in Patients with Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis

Shaofan Zhang,1 Li Shi,1 Dan Mao,1 Weijun Peng,1 Chenxia Sheng,1 Chenchen Ding,1 Fengxia Lin,2 Caiyun Lei,1 and Sifang Zhang1

1Department of Integrated Chinese and Western Medicine, The Second Hospital of Xiangya, Central South University, Changsha 410008, China
2Department of Cardiology, Affiliated Baolian TCM Hospital, Guangzhou University of Traditional Chinese Medicine, Shenzhen, Guangdong, China

Correspondence should be addressed to Sifang Zhang; sifangzhang2005@csu.edu.cn

Received 3 May 2017; Revised 16 December 2017; Accepted 26 December 2017; Published 29 January 2018

Copyright © 2018 Shaofan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To systematically review the effect of invigorating Pi and detoxification (Jianpi Jiedu, [JPJD]) herbs in advanced colorectal cancer (CRC) patients receiving chemotherapy. Methods. Three English and four Chinese databases were searched. Literature was screened by EndNote X7 and data were analyzed by RevMan 5.2. Results. This review comprised 12 randomized clinical studies of 701 patients. The results showed that JPJD herbs improved the therapeutic effect on Chinese medicine symptoms [risk ratio (RR) = 1.59; 95% confidence interval (CI): 1.35∼1.88] and Karnofsky performance score [RR = 2.07; 95% CI: 1.52∼2.82] for advanced CRC patients receiving chemotherapy, lowered the Chinese medicine symptoms’ score [weighted mean difference = −2.44; 95% CI: −3.23∼−1.64], reduced the incidence of nausea and vomiting [RR = 0.23; 95% CI: 0.11∼0.49], improved platelet toxicity grades III-IV [odds ratio = 0.29; 95% CI: 0.12∼0.74] and I–IV [RR = 0.65; 95% CI: 0.51∼0.82], and improved white blood cell toxicity grades III-IV [RR = 0.37; 95% CI: 0.23∼0.58] and I–IV [RR = 0.69; 95% CI: 0.60∼0.79]. However, the results showed no significant effect on tumor response. Conclusion. JPJD herbs can improve quality of life, relieve symptoms, and reduce adverse events of advanced CRC patients receiving chemotherapy.

1. Introduction

Colorectal cancer (CRC), including colon and rectal cancer, is typically a malignancy of the intestinal epithelial mucosa and is one of the most common gastrointestinal malignancies. CRC is the third most common type of malignant tumor in China [1]. Worldwide, after lung and breast cancer, CRC is the most prominent cancer impacting disability-adjusted life years (DALY) [2]. According to the International Agency for Research on Cancer (IARC), in 2012, there were estimated to be 1.36 million new cases and 0.69 million deaths from CRC worldwide [3]. Currently, CRC treatment options include surgery, chemotherapy, radiotherapy, or a combination of the three [4, 5]. Surgery is usually the first option, with the excision rate reaching 60∼70% [6]. However, more than half of these patients relapse or present with metastases in 5 years, ultimately succumbing to the disease. In China, CRC is most prevalent in those aged 40–60 years. Due to its occult onset and poor patient awareness of the disease, most are diagnosed at an advanced stage [7]. In such cases, it is usually too late for surgery, with chemotherapy being the main form of adjuvant therapy [8]. Chemotherapy can prolong survival and a randomized crossover trial has shown that patients receiving chemotherapy, in any sequence, survive a median period of over 20 months [9]. Unfortunately, chemotherapy of CRC is often ineffective due to the intrinsic chemoresistance of the tumor [10]. Overall CRC survival rates are unsatisfactory, especially for late-stage disease [11]. Hence, it is imperative to develop more effective treatments for CRC. Multiple studies [12–14] have demonstrated traditional Chinese medicine (TCM) to enhance efficacy and to decrease the toxicity of chemotherapy. TCM has been shown to alleviate symptoms, improve quality of life, enhance immune function, and relieve the adverse effects of chemotherapy.
2. Methods

2.1. Database and Search Strategy. A comprehensive literature review was conducted on RCTs that combined treatments (JPJD herbs plus chemotherapy) for advanced CRC. Various databases were searched from the inception to March 2017, including the Cochrane Library, the Excerpta Medica Database (EMBASE), the Chinese Biomedical Literature Database (CBM), Wanfang Data (for unpublished graduate theses in China), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and PubMed/MEDLINE. The basic terms used were the following: (“Colonic Neoplasms” OR “Colonic Neoplasm” OR “Colon Neoplasms” OR “Colon Neoplasm” OR “Cancer of Colon” OR “Colon Cancers” OR “Cancer of the Colon” OR “Colonic Cancer” OR “Colorectal cancer” OR “Colonic Cancers” OR “colorectal cancer”) AND (“Chinese medicine” OR “Chinese herbal medicine” OR “Jianpi” OR “Jiedu”). Two reviewers (Shaofan Zhang and Li Shi) separately searched the literature screening and data extraction (using Excel) was performed by two independent reviewers (Shaofan Zhang and Li Shi). Selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting), and other biases (determined according to sample size calculation method, inclusion/exclusion of criteria for patient’s recruitment, comparability of baseline data, funding sources, and any other potential methodological flaw that might have influenced the overall assessment) were evaluated according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions [21]. Three potential bias judgments, low risk, high risk, and unclear risk, were determined for each trial. A judgment of low risk was made when all the items met the criteria of “low risk,” and a judgment of high risk for bias was made when at least one of the items was assessed as “high risk” [22, 23]. All risks for biased data are presented in Figures 2 and 3. Disagreements between the two reviewers were resolved by discussion with a third reviewer (Dan Mao).

2.2. Inclusion Criteria. The included studies met the following criteria: (1) randomized controlled trial (RCT); (2) diagnosis confirmed as advanced CRC, according to “New Criteria for the Diagnosis and Treatment of Common Malignant Tumors” [18], “Clinical Guidelines for new drugs in Traditional Chinese medicine” [19], and “Internal Medicine of Traditional Chinese Medicine” [20]; (3) intervention by administration of a Chinese medicine (CM) decoction with JPJD herbs and chemotherapy to patients (the treatment group), where the specific chemotherapy regimen in each study was not limited; (4) outcomes measured as follows: CM symptoms score, therapeutic effect of CM symptoms, performance status, adverse events (AEs) of chemotherapy, and tumor response.

2.3. Exclusion Criteria. The excluded studies were excluded due to the following reasons: (1) studies did not meet the above criteria; (2) Chinese herbal medicine (CHM) was used in both the intervention group and the control group; (3) the study was not an original research (e.g., review article and letter to the editor); (4) studies were duplicated publications or articles without specific data; (5) there were no specific criteria for inclusion or exclusion; (6) they were laboratory studies.

2.4. Quality Assessment and Data Extraction. The process of literature screening and data extraction (using Excel) was carried out by two independent reviewers (Shaofan Zhang and Li Shi). Selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting), and other biases (determined according to sample size calculation method, inclusion/exclusion of criteria for patient’s recruitment, comparability of baseline data, funding sources, and any other potential methodological flaw that might have influenced the overall assessment) were evaluated according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions [21]. Three potential bias judgments, low risk, high risk, and unclear risk, were determined for each trial. A judgment of low risk was made when all the items met the criteria of “low risk,” and a judgment of high risk for bias was made when at least one of the items was assessed as “high risk” [22, 23]. All risks for biased data are presented in Figures 2 and 3. Disagreements between the two reviewers were resolved by discussion with a third reviewer (Dan Mao).

2.5. Statistical Analysis. EndNote X7 (Thomson Reuters, USA) was used to manage the articles and the Cochrane Collaboration software (RevMan 5.2) was used to perform the statistical analysis. Weighted mean differences (WMD) with 95% confidence interval (CI) were calculated for continuous data, and standardized WMD (SMD) was calculated for data measured in different ways by each trial. Dichotomous data were expressed as relative risk (RR) or odds ratio (OR) with 95% confidence interval (CI). χ² test and I² test were used to assess the heterogeneity of the data. If heterogeneity existed in pooled studies (I² ≥ 50%), a random model was applied; if not, a fixed model was applied. Statistically significant difference was considered as p < 0.05.

3. Results

3.1. Search Results and Study Characteristics. In this study, 1221 citations were identified through the electronic databases (the Cochrane Library, EMBASE, CBM, WF, CNKI, VIP, and PubMed/MEDLINE). Of these, 142 were rejected following duplicate checking with EndNote X7. Potentially relevant articles (n = 156) were retrieved through title and abstract checking. Each of these was assessed in detail. Articles relevant to “Jianpi” or “Jiedu” (n = 75) remained after further screening. Of these, 63 full-text articles did not fully meet inclusion criteria or were duplicate publications. Finally, only 12 studies [24–35] fulfilled the eligibility criteria.
After searching the databases, we identified articles:
PubMed \(N = 167\)
The Cochrane Library \(N = 42\)
CBM \(N = 40\)
CNKI \(N = 578\)
VIP \(N = 165\)
WF \(N = 209\)

Records after duplicates were removed by EndNote
\(N = 1079\)

Records screened out after reading titles and abstracts:
Nonrandomized control trials, case reports, reviews, expert experience, basic/mechanism studies, protocol
\(N = 923\)

Full-text articles assessed for eligibility:
\(N = 156\)

144 full-text articles do not fully fulfill the inclusion criteria or were duplicated publications

Final included articles in the review:
\(N = 12\)

**Figure 1:** Flow diagram of included studies in the meta-analysis (up to March 2017).

A total of 701 patients were enrolled in the studies, of which 355 patients participated in chemotherapy combined with JPJD herbs (CTJ) and 346 received chemotherapy alone. Figure 1 illustrates the process of literature screening and Table 1 shows the main characteristics of each trial included in the meta-analysis.

3.2. Risk of Bias. In general, the risk of bias in all 12 included articles was unclear or high in that limited information was available to the reviewers. Twelve studies mentioned randomization, but only 4 trials [24, 27, 29, 32] included a detailed description of the randomization method. These were considered as low risk and were divided into groups by random order. No study showed allocation concealment. Attempts to contact the authors by phone or e-mail were unsuccessful. Blinding did not apply to these cited studies or to withdrawals, follow-up, or intention-to-treat analysis. Study protocols were not available for any included studies. Therefore, it was not possible to evaluate whether all expected outcomes were reported. As such, all the studies were considered as high risk. Zhu et al.’s study [34] was considered as high risk for selection bias in that the admission number was also the randomization method. All the included studies were graded according to the Cochrane Handbook 5.0. Figures 2 and 3 show the authors’ judgment of the quality of each methodological parameter.

3.3. Effects of the Intervention

3.3.1. Tumor Response. As shown in Figure 4, there was no significant effect on complete response (CR) or partial response (PR) within the CTJ group (risk ratio (RR) = 1.30; 95% CI: 1.05–1.61; \(p = 0.02\); 11 studies [24–32, 34, 35], 649 patients). In these studies, there was no statistically significant effect of JPJD herbs on advanced CRC.

3.3.2. Life Status. Two types of Karnofsky performance score (KPS) data were reported in the studies: improvements in KPS and KPS data before and after treatment. Only four [31–34] of the 12 studies mentioned an improvement in KPS. For the CTJ group (\(n = 169\)), 50.89% of patients reported improved KPS data. For the chemotherapy group (\(n = 159\)), 24.53% of the patients reported improved KPS data. Thus, there was a significant improvement in the CTJ group (RR = 2.07; 95% CI: 1.52–2.82; \(p < 0.00001\); four studies, 328
| Study ID               | Age (yrs) | Sample size (T/C) | Gender (M/F) | Study design (E/C) | Control group | Intervention | Experiment group | Treatment session | Main outcomes                                                                 |
|-----------------------|-----------|-------------------|--------------|-------------------|---------------|--------------|-----------------|-------------------|-----------------------------------------------------------------------------|
| Lai, 2012, China      | 30–73     | 30/30             | 38/22        | Parallel-group    | FOLFOX4       | FOLFOX4 + CHM |                 | 8 weeks           | Tumor response, AEs, KPS                                                   |
| Fan, 2013, China      | 48–73     | 20/20             | 22/48        | Parallel-group    | L-OHP + S-1   | L-OHP + S-1 + CHM |                 | 3 weeks           | Tumor response, AEs, KPS, CM symptoms score, therapeutic effect of CM symptoms |
| Zhao, 2015, China     | 48–67     | 30/30             | 39/21        | Parallel-group    | FOLFIRI       | FOLFIRI + CHM |                 | 6 weeks           | AE, KPS, therapeutic effect of CM symptoms, QLQ-C, serum CEA                |
| Zhang, 2009, China    | 44–70     | 20/20             | 22/38        | Parallel-group    | OLF           | OLF + CHM     |                 | 6 weeks           | Tumor response, AEs, KPS, therapeutic effect of CM symptoms, FACT-C, serum CEA |
| Yuan, 2010, China     | 48–71     | 15/15             | 12/18        | Parallel-group    | FOLFIRI       | FOLFIRI + CHM |                 | 8 weeks           | Tumor response, AEs, KPS, therapeutic effect of CM symptoms, QLQ-C30       |
| Zhu, 2012, China      | 49–71     | 20/20             | 32/08        | Parallel-group    | FOLFIRI       | FOLFIRI + CHM |                 | 6 weeks           | Tumor response, AEs, KPS, therapeutic effect of CM symptoms, serum CEA       |
| Zhang et al., 2013,   | 50–78     | 30/30             | 31/29        | Parallel-group    | Capecitabine  | Capecitabine + CHM |                 | 6 weeks           | Tumor response, CM symptoms score, therapeutic effect of CM symptoms, AEs, EOTRC-QLQ-C30 |
| China [30]            |           |                   |              |                   |               |              |                 |                   |                                                                            |
| Zhang et al., 2010,   | NA        | 21/20             | NA           | Parallel-group    | FOLFIRI       | FOLFIRI + CHM |                 | 4 weeks           | Tumor response, AEs, KPS                                                   |
| China [31]            |           |                   |              |                   |               |              |                 |                   |                                                                            |
| Zhang et al., 2015,   | NA        | 95/87             | 105/77       | Parallel-group    | FOLFIRI/XELOX/FOLFIRI/FOLFIRI + CHM | FOLFIRI/XELOX/FOLFIRI/FOLFIRI + CHM |                 | NA                | Tumor response, AEs, KPS                                                   |
| China [32]            |           |                   |              |                   |               |              |                 |                   |                                                                            |
| Li, 2010, China       | 25–70     | 26/25             | 14/37        | Parallel-group    | OLF           | OLF + CHM     |                 | 6 weeks           | AEs, KPS, FACT-C, QOL, serum CEA and CA199                                   |
| Zhu et al., 2016,     | 34–73     | 27/27             | 36/18        | Parallel-group    | mFOLFIRI      | mFOLFIRI + CHM |                 | 8 weeks           | Tumor response, AEs, KPS                                                   |
| China [34]            |           |                   |              |                   |               |              |                 |                   |                                                                            |
| Yao and Ren, 2014,    | 47–72     | 21/21             | 22/20        | Parallel-group    | XELOX         | XELOX + CHM   |                 | 6 weeks           | Tumor response, AEs, CM symptoms score, therapeutic effect of CM symptoms |
| China [35]            |           |                   |              |                   |               |              |                 |                   |                                                                            |

Notes: E/C: experiment group/control group; M/F: male/female; CHM: Chinese herbal medicine; N/V: nausea and vomiting; NA: not available; AEs: adverse events; QOL: quality of life; FACT-P: functional assessment of cancer therapy-prostate; QLQ-C: quality of life questionnaire-cancer; KPS: Karnofsky performance score.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other biases

| Component                               | Low risk of bias | Unclear risk of bias | High risk of bias |
|-----------------------------------------|------------------|----------------------|-------------------|
| Random sequence generation              | ☑️               | ☑️                   | ☑️                |
| Allocation concealment                  | ☑️               | ☑️                   | ☑️                |
| Blinding of participants and personnel  | ☑️               | ☑️                   | ☑️                |
| Blinding of outcome assessment          | ☑️               | ☑️                   | ☑️                |
| Incomplete outcome data                 | ☑️               | ☑️                   | ☑️                |
| Selective reporting                     | ☑️               | ☑️                   | ☑️                |
| Other biases                            | ☑️               | ☑️                   | ☑️                |

**Figure 2:** Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.

**Figure 3:** Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
patients) (see Figure 5). There was no heterogeneity among these studies ($\chi^2 = 1.45$, $p = 0.69$, and $I^2 = 0\%$).

Pretreatment KPS data were reported for six studies [26–29, 33, 35] and posttreatment KPS data were reported for seven studies [24, 26–29, 33, 35]. Pretreatment KPS data were not significantly different between the CTJ and chemotherapy groups (WMD = −0.63; 95% CI: −1.29–0.04; $p = 0.07$; $I^2 = 0\%$) (see Figure 6). Heterogeneity among the seven studies was low ($\chi^2 = 7.62$, $p = 0.27$, and $I^2 = 21\%$) and a significant improvement in the CTJ group after treatment was observed (WMD = 6.79; 95% CI: 6.18–7.40; $p < 0.00001$; $I^2 = 21\%$) (see Figure 7).

3.3.3. CM Symptoms’ Score and Therapeutic Effect on CM Symptoms. For analysis of CM symptoms’ scores, four studies [25, 27, 30, 35] comprising 182 patients were assessed, with 91 patients in the treatment group and 91 patients in the control group. The heterogeneity test showed $\chi^2 = 2.38$, $p = 0.50$, and $I^2 = 0\%$ (see Figure 8). The pooled studies showed a significant decline in the CTJ group (WMD = −2.44; 95% CI: −3.23–−1.64; $p < 0.00001$; $I^2 = 0\%$). Seven studies [25, 27–30, 33, 35] mentioned a therapeutic effect on CM symptoms. The heterogeneity test showed no heterogeneity ($\chi^2 = 3.91$, $p = 0.69$, and $I^2 = 0\%$) (see Figure 9). The pooled studies showed a significant rise in the CTJ group (RR = 1.59; 95% CI: 1.35–1.88; $p < 0.00001$; $I^2 = 0\%$). As shown in the two pooled studies, JPJD herbs improved CM symptoms of advanced CRC patients treated with chemotherapy, although the effect was moderate.
### 3.3.4. Adverse Events (AEs).

For the evaluation of nausea and vomiting (N/V) at grades III-IV, nine studies [24–28, 31–34] comprising 418 patients were assessed. Of those patients, 210 were in the treatment group and 208 were in the control group. The heterogeneity test showed $\chi^2 = 0.64$, $p = 1.0$, and $I^2 = 0\%$ (see Figure 10). Due to the homogeneity of studies, RR was determined by a fixed-effects model ($RR = 0.23; 95\% CI: 0.11–0.49; p = 0.0001$). JPJD herbs reduced the incidence of N/V induced by chemotherapy, although the effect was moderate.

Two platelet (PLT) stages were reported in these trials. PLT reductions at toxicity grades III-IV were assessed in 10 studies [24–29, 31–34] comprising 598 patients, of which 304 were in the treatment group and 294 were in the control group. The heterogeneity test showed $\chi^2 = 2.38$, $df = 3 (p = 0.50); I^2 = 0\%$. Due to the homogeneity of studies, RR was determined by a fixed-effects model ($RR = 0.23; 95\% CI: 0.11–0.49; p = 0.0001$). JPJD herbs reduced the incidence of N/V induced by chemotherapy, although the effect was moderate.
### Table 1: Forest plot of the risk ratio (RR) for therapeutic effect on Chinese medicine (CM) symptoms associated with advanced CRC patients.

| Study or subgroup | Experimental Events | Total | Control Events | Total | Weight | Risk ratio M-H, fixed, 95% CI | Risk ratio M-H, fixed, 95% CI |
|------------------|---------------------|-------|----------------|-------|--------|-----------------------------|-----------------------------|
| Fan, 2013, China [25] | 18              | 20    | 10             | 20    | 12.3%  | 1.80 [1.13, 2.86]           |                             |
| Zhao, 2015, China [26] | 24              | 30    | 14             | 30    | 17.3%  | 1.71 [1.12, 2.62]           |                             |
| Zhang, 2009, China [27] | 18              | 20    | 12             | 20    | 14.8%  | 1.50 [1.02, 2.21]           |                             |
| Yuan, 2010, China [28] | 13              | 15    | 9              | 15    | 11.1%  | 1.44 [0.91, 2.28]           |                             |
| Zhu, 2012, China [29] | 18              | 20    | 8              | 20    | 9.9%   | 2.25 [1.29, 3.92]           |                             |
| Zhang et al., 2013, China [30] | 19            | 30    | 16             | 30    | 19.8%  | 1.19 [0.77, 1.83]           |                             |
| Yao and Ren, 2014, China [35] | 19            | 21    | 12             | 21    | 14.8%  | 1.58 [1.07, 2.35]           |                             |
| Total (95% CI)          | 156             | 156   | 100.0%         |       | 1.59 [1.35, 1.88]           |                             |
| Total events            | 129             | 81    |                |       |        |                             |                             |

Heterogeneity: \( \chi^2 = 3.91; \text{df} = 6 (p = 0.69); I^2 = 0\%

Test for overall effect: \( Z = 5.46 (p < 0.00001) \)

**Figure 9:** Forest plot of the risk ratio (RR) for therapeutic effect on Chinese medicine (CM) symptoms associated with advanced CRC patients. Notes: the box represents the OR/RR/WMD point estimate of each study, and its area is proportional to the weight of the estimate. Horizontal lines represent the 95% confidence interval (CI).

---

### Table 2: Forest plot of the risk ratio (RR) for nausea and vomiting (N/V) at grades III-IV associated with advanced CRC patients.

| Study or subgroup | Experimental Events | Total | Control Events | Total | Weight | Risk ratio M-H, fixed, 95% CI | Risk ratio M-H, fixed, 95% CI |
|------------------|---------------------|-------|----------------|-------|--------|-----------------------------|-----------------------------|
| Lai, 2012, China [24] | 3                | 30    | 12             | 30    | 36.8%  | 0.25 [0.08, 0.80]           |                             |
| Fan, 2013, China [25] | 0                | 20    | 4              | 20    | 13.8%  | 0.11 [0.01, 1.94]           |                             |
| Zhao, 2015, China [26] | 1                | 30    | 3              | 30    | 9.2%   | 0.33 [0.04, 3.03]           |                             |
| Zhang, 2009, China [27] | 1               | 20    | 3              | 20    | 9.2%   | 0.33 [0.04, 2.94]           |                             |
| Yuan, 2010, China [28] | 0                | 15    | 0              | 15    | Not estimable |                           |                             |
| Zhang et al., 2010, China [31] | 0            | 21    | 1              | 20    | 4.7%   | 0.32 [0.01, 7.38]           |                             |
| Li, 2010, China [33] | 0                | 26    | 2              | 25    | 7.8%   | 0.19 [0.01, 3.82]           |                             |
| Zhu et al., 2016, China [34] | 1               | 27    | 6              | 27    | 18.4%  | 0.17 [0.02, 1.29]           |                             |
| Yao and Ren, 2014, China [35] | 0            | 21    | 0              | 21    | Not estimable |                           |                             |
| Total (95% CI)          | 210             | 208   | 100.0%         |       | 0.23 [0.11, 0.49]           |                             |
| Total events            | 6                | 31    |                |       |        |                             |                             |

Heterogeneity: \( \chi^2 = 0.64; \text{df} = 6 (p = 1.00); I^2 = 0\%

Test for overall effect: \( Z = 3.81 (p < 0.0001) \)

**Figure 10:** Forest plot of the risk ratio (RR) for nausea and vomiting (N/V) at grades III-IV associated with advanced CRC patients. Notes: the box represents the OR/RR/WMD point estimate of each study, and its area is proportional to the weight of the estimate. Horizontal lines represent the 95% confidence interval (CI).

---

Further analysis of the data revealed that...
Table 1: Forest plot of the odds ratio (OR) for platelets (PLT) reductions at the toxicity grades III–IV associated with advanced CRC patients.

- **Study or subgroup:** Lai, 2012, China [24]  
  2 30 9 30 44.5%  
  0.17 [0.03, 0.85]  

- **Study or subgroup:** Fan, 2013, China [25]  
  0 20 0 20 100.0%  
  0.12 [0.03, 0.49]  

- **Study or subgroup:** Zhao, 2015, China [26]  
  0 30 2 30 13.0%  
  0.19 [0.01, 4.06]  

- **Study or subgroup:** Zhang, 2009, China [27]  
  0 20 0 20 100.0%  
  0.17 [0.03, 0.85]  

- **Study or subgroup:** Yuan, 2010, China [28]  
  0 15 0 15 100.0%  
  0.19 [0.01, 4.06]  

- **Study or subgroup:** Zhu, 2012, China [29]  
  0 20 1 20 7.8%  
  0.10 [0.01, 0.85]  

- **Study or subgroup:** Zhang et al., 2010, China [31]  
  1 21 1 20 5.2%  
  0.10 [0.01, 0.85]  

- **Study or subgroup:** Zhang et al., 2015, China [32]  
  2 95 4 87 21.7%  
  0.10 [0.01, 0.85]  

- **Study or subgroup:** Li, 2010, China [33]  
  0 27 1 27 7.8%  
  0.10 [0.01, 0.85]  

**Total (95% CI)**  
304 294 100.0% 0.29 [0.12, 0.74]

**Figure 11:** Forest plot of the odds ratio (OR) for platelets (PLT) reductions at the toxicity grades III–IV associated with advanced CRC patients. Notes: the box represents the OR/RR/WMD point estimate of each study, and its area is proportional to the weight of the estimate. Horizontal lines represent the 95% confidence interval (CI).

### 4. Discussion

In recent years, multidisciplinary teams (MDTs) have made significant improvements in evidence-based decision-making [36], which have improved and controlled the condition of advanced CRC patients. TCM may enhance the efficacy of both chemotherapy and radiotherapy [37]. In China, TCM is an important component of the combined therapy of CRC, which results in a reduction in the toxicity associated with chemotherapy [38]. As such, TCM should be part of MDT, allowing for better decision-making.

Chemotherapy is one of the main therapies for treatment of advanced CRC. Combination therapies of fluorouracil with leucovorin and either irinotecan (FOLFIRI regimen [39]) or oxaliplatin (mFOLFOX6 regimen [40]) have become the main CRC chemotherapeutic treatment options. Studies [41, 42] have shown that postoperative CRC patients treated with chemotherapy exhibit bone marrow suppression, gastrointestinal reactions, and other adverse events. In addition, Chinese medicine (CM) experts [43] believe that bone marrow suppression may be caused by spleen deficiency and toxic heat. Invigorating the spleen and detoxification may
be key to treating advanced CRC. Hence, this meta-analysis was performed to provide evidence for the use of herbs in advanced CRC patients receiving chemotherapy, that is, Jianpi Jiedu (JPJD), a TCM principle.

In the evaluated trials, prescriptions for JPJD herbs were Astragalus, Codonopsis, Oldenlandia diffusa, Atractylodes, Poria cocos, and Radix Actinidia. These herbs can improve the immune system, alleviate adverse events, improve quality of life, or even be a potential cure. For example, macrocephala polysaccharide is refined from Atractylodes. Mao et al. [44] and Tang [45] have suggested that macrocephala polysaccharide of Atractylodes can comprehensively enhance the immunity of mice. Tseng et al. [46] found that an Astragalus membranaceous extract could inhibit the growth of CRC in vivo without apparent toxicity or side effects. Lu et al. [47] found Oldenlandia diffusa extracts to inhibit CRC cells in vitro and in vivo, possibly via activation of AMP-activated protein kinase- (AMPK-) dependent signaling. Kim et al. [48]...
suggested that an ethanol extract of *Oldenlandia diffusa* may be an effective chemotherapeutic agent for the treatment of human CRC.

This meta-analysis demonstrated JPJD herbs to result in a significant improvement in KPS, a significant improvement in posttreatment KPS \((p < 0.00001)\), a significant decline in CM symptoms’ score, and a significant rise in the therapeutic effect on CM symptoms \((p < 0.00001)\). These results demonstrate the ability of JPJD herbs to alleviate CM symptoms and to improve the KPS of advanced CRC patients undergoing chemotherapy.

Adverse events improved by JPJD herbs were as follows: (1) nausea and vomiting (N/V) at toxicity grades III-IV, (2) reduced PLT numbers at toxicity grades III-IV, (3) decreased PLT numbers at toxicity grades I–IV, (4) decreased WBC at toxicity grades III-IV, (5) and decreased WBC at toxicity grades I–IV. These effects were significant when compared to the control group, which indicates that JPJD herbs reduce the incidence rate of AEs. Analysis of the tumor response to JPJD herbs is ongoing, but no statistically significant effect has been observed to date \((p = 0.02)\).

There are many quality of life (QOL) questionnaires, although the European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30 or CR38 is often used. However, the onset, characteristics, and interventions for CRC in China are significantly different from those in Europe and the United States \([49]\). Use of the KPS scale for QOL evaluation is most commonly used by domestic researchers. However, the KPS scale considers only a portion of QOL and does not fully reflect all characteristics of CM. It does not include the patient’s subjective feelings, psychological status, or social status and as such is not comprehensive. In order to accurately assess symptom differences before and after treatment, the CM symptoms’ score and the therapeutic effect on CM symptoms were evaluated. The standard table used to score CM symptoms for CRC includes abdominal pain, diarrhea, constipation, anorexia, fatigue, weight loss, nausea, and vomiting. The standard table used to score the therapeutic effect of CM symptoms for CRC includes sallow complexion, fatigue, inappetence, abdominal pain, dry stool, thin sloppy stool, and hemafecia. The two tables differ and either one of them, or both, is chosen by Chinese medicine experts and Chinese medicine researchers. The effects of JPJD herbs on individual symptoms are evaluated below in greater depth.

The anticancer effect of chemotherapy on CRC is the inhibition of DNA synthesis as well as inhibition of the replication of cancer cells \([50]\). Resultant adverse events include marrow suppression, gastrointestinal reactions, and neurotoxicity. According to “Acute and Sub-acute Reaction Standards for Antineoplastic Agents” from the World Health Organization (WHO), nausea and vomiting, two stages of PLT, and WBC are the major indices of adverse events. This meta-analysis found JPJD herbs to impact bone marrow suppression and the incidence of nausea and vomiting caused by chemotherapy.

As for the tumor response, the reasons why the outcomes are negative may be intrinsic to culture and to system. Differences between traditional Chinese medicine and Western medicine may explain why no tumor response was observed with JPJD herbs. The therapeutic effect of traditional Chinese medicine on tumors is mainly through regulation of the body’s internal environment. The purpose is to bring Pi and blood, Yin and Yang, and Zang and Fu into harmony, with the goal of tumor inhibition. Solid tumor parameters are the measures used in Western medicine to assess the tumor response, which is in line with international standards. However, this measurement fails to reflect the approach of traditional Chinese medicine. Some researchers use standards of their own, which may reduce credibility and may be unreliable. In the future, it will be important to design effective and reliable standards that can be applied to traditional Chinese medicine.

The literature related to the use of JPJD herbs in patients with advanced CRC was collected through manual and electronic databases. A formal data extraction table was designed to extract data for quantitative analysis. The search process, the accuracy of the data extraction, and quality assessment were undertaken by two reviewers. Disagreements between the two reviewers were resolved by discussion with a third reviewer. However, this approach does have several limitations and shortcomings. First, the search strategy was restricted to articles published in English or Chinese language, and 12 studies were published exclusively in China. Hence, publication bias may exist. Second, the trial samples sizes varied from 40 to 60 patients (only one trial included 182 subjects) and as such were quite small, with results inconsistent among the trials. Therefore, there may be reporting bias. Third, there may have been information bias in that only limited information was disclosed and only four of the trials used randomization of subjects. None of the selected trials reported allocation concealment or the blinding process. Attempts to contact the authors for more information by phone or e-mail were unsuccessful. Hence, there was a high risk for selection and performance bias in the studies covered by this review. Fourth, only four studies reported improvement in KPS, and only four studies reported the CM symptoms’ score. Ten studies reported effects on PLTs, but four of these did not include patient characteristics. No trial reported measures of mortality. All trials reported AEs in the trial and control groups. Selective reporting of outcomes limited an integrated analysis, as did the low quality scores of the included trials.

5. Conclusion

This meta-analysis demonstrates the capability of JPJD herbs, when combined with chemotherapy, to increase KPS, increase the therapeutic effect on CM symptoms, decrease the CM symptoms’ score, and decrease the rate of AEs. However, due to the complex nature of Chinese herbal medicine (CHM) interventions, further evidence needs to be obtained from high-quality trials with larger sample sizes.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Authors’ Contributions

All authors were involved in drafting and/or revising the manuscript for intellectual content. All authors approved the final version. Sifang Zhang and Shaofan Zhang designed the review protocol. Shaofan Zhang, Li Shi, and Dan Mao conducted the literature search. Shaofan Zhang, Li Shi, Dan Mao, Chenchen Ding, Fengxia Lin, Caiyun Lei, and Sifang Zhang contributed to data extraction. Shaofan Zhang, Li Shi, Dan Mao, and Sifang Zhang contributed to quality assessment. Shaofan Zhang performed the analyses and drafted the manuscript. Weijun Peng, Sifang Zhang, Dan Mao, and Chenxia Sheng revised the paper.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81273722).

References

[1] Z. Dai, R. S. Zheng, and X. N. Zou, “Analysis and prediction of colorectal cancer incidence trend in China,” Zhonghua Yu Fang Yi Xue Za Zhi, vol. 46, no. 7, pp. 598–603, 2012.
[2] I. Soerjomataram, J. Lorert-Tieulent, D. M. Parkin et al., “Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions,” The Lancet, vol. 380, no. 9856, pp. 1840–1850, 2012.
[3] International Agency for Research on Cancer (IARC), “Colorectal Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012,” 2012.
[4] I. Leake, “Colorectal cancer: Understanding the routes of metastasis in colorectal cancer,” Nature Reviews Gastroenterology & Hepatology, vol. 11, no. 5, p. 270, 2014.
[5] J. M. Hubbard and A. Grothey, “Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies,” Nature Reviews Clinical Oncology, vol. 12, no. 2, pp. 73–74, 2015.
[6] J. G. Docherty, J. R. McGregor, P. J. O’Dwyer, and D. J. Galloway, “Local recurrence of colorectal cancer: The problem, mechanisms, management and adjuvant therapy,” British Journal of Surgery, vol. 81, no. 7, pp. 1082-1082, 1994.
[7] T. Tian, C. Chen, F. Yang et al., “Establishment of apoptotic regulatory network for genetic markers of colorectal cancer and optimal selection of traditional Chinese medicine target,” Saudi Journal of Biological Sciences, vol. 24, no. 3, pp. 634–643, 2017.
[8] H. Y. Shi and Z. F. Xu, “Research progress of chemotherapy to colorectal cancer,” Chinese Journal of Cancer Prevention and Treatment, vol. 19, pp. 1913–1918, 2012.
[9] C. Tournigand, T. André, E. Achille et al., “FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study,” Journal of Clinical Oncology, vol. 22, no. 2, pp. 229–237, 2004.
[10] S. K. Chan, O. L. Griffith, I. T. Tai, and S. J. M. Jones, “Metanalysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers,” Cancer Epidemiology, Biomarkers & Prevention, vol. 17, no. 3, pp. 543–552, 2008.
[11] J. B. O’Connell, M. A. Maggard, and C. Y. Ko, “Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging,” Journal of the National Cancer Institute, vol. 96, no. 19, pp. 1420–1425, 2004.
A. De Gramont, A. Figer, M. Seymour et al., "Leucovorin and X. J. Jin, H. Wang, and W. D. Li, "Observation of 33 cases W. W. Zhang, J. Chen, and G. Q. Xie, "Clinical study of C. Taylor, A. J. Munro, R. Glynne-Jones et al., "Multidisciplinary L. Zhu, D. Yuan, J. H. Zhao, J. L. Wei, and T. J. Zhang, "Effect of Shengyu H. R. Liu, H. Y. Liu, R. C. Wang et al., "Clinical study of Jianpi Jiedu Y. B. Zhang, X. Liu, and Q. Ji, "Clinical research on treating C. Yao and H. C. Ren, "Clinical observation of 21 cases advanced colorectal cancer patients with combined traditional Chinese and western medicine treatment," Y. Zhang, J. H. Xu, and Y. Sun, "Clinical study of Jianpijiedu-Decoction plus FOLFOX4 regimen in the treatment of advanced colorectal cancer," Global Traditional Chinese Medicine, vol. 3, no. 2, pp. 117–120, 2010. Y. B. Zhang, X. Liu, and Q. Ji, "Clinical research on treating metastatic colorectal cancer with Jianpi Jiedu decoction and chemotherapy," Journal of Chinese Medicine, vol. 30, no. 06, pp. 2090–2093, 2015. P. Y. Li, Clinical studies on impact of quality of life of Jianpi Jiedu Huayu therapy in the treatment of patients with advanced colorectal cancer, Nanjing University of Chinese Medicine, 2010. Y. Zhu, B. Wang, and Y. Ai, "Clinical study of JianPiYiQiJieDu Decoction with chemotherapy in the treatment of patients with advanced colorectal tumor," Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 25, no. 03, pp. 261–263, 2016. C. Yao and H. C. Ren, "Clinical observation of 21 cases advanced colorectal cancer patients with combined traditional Chinese and western medicine treatment," Journal of New Chinese Medicine, vol. 46, no. 12, pp. 161-163, 2014. C. Taylor, A. J. Munro, R. Glynn-Jones et al., "Multidisciplinary team working in cancer: what is the evidence?" BMJ, vol. 340, c951 pages, 2010. M. McCulloch, C. See, X. Shu et al., "Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials," Journal of Clinical Oncology, vol. 24, no. 3, pp. 419–430, 2006. H. R. Liu, H. Y. Liu, R. C. Wang et al., "Clinical study of Chinese medicine attenuated synergistic effect on colorectal cancer after operation," Journal of Hebei Traditional Chinese Medicine and Pharmacology, vol. 28, pp. 12-13, 2013. J. Y. Douillard, D. Cunningham, A. D. Roth et al., "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial," The Lancet, vol. 355, no. 9209, pp. 1041–1047, 2000. A. De Gramont, A. Figer, M. Seymour et al., "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer," Journal of Clinical Oncology, vol. 18, no. 16, pp. 2938–2947, 2000. W. B. Chen and G. J. Zhu, "Effect of Shengyu Decoction on spleen index and tissue pathology of bone marrow depression," Journal of Emergency in Traditional Chinese Medicine, vol. 6, pp. 928–930, 2013. J. H. Mao, Z. L. Lv, and Q. L. Zeng, "Effects of the polysaccharide of Atractylis macrocephala Koidz on the function of mouse T lymphocyte," Immunological Journal, vol. 12, no. 4, 1996. X. H. Tang, "The influence of macrocephala polysaccharide of atractyloide on the immune function of mice," Traditional Chinese Medicinal Research, vol. 11, 1998. A. Tseng, C.-H. Yang, C.-H. Chen et al., "An in vivo molecular response analysis of colorectal cancer treated with Astragalus membranaceus extract," Oncology Reports, vol. 35, no. 2, pp. 659–668, 2016. P.-H. Lu, M.-B. Chen, C. Ji, W.-T. Li, M.-X. Wei, and M.-H. Wu, "Aqueous Oldenlandia diffusa extracts inhibits colorectal cancer cells via activating AMP-activated protein kinase signalings," Oncotarget, vol. 7, no. 29, pp. 45889–45900, 2016. B. J. Kim, S. Lee, J. H. Shim, H. Gim, and H. S. Park, "Ethanol extract of oldenlandia diffusa—an effective chemotherapeutic for the treatment of colorectal cancer in humans," Journal of Pharmacopuncture, vol. 19, no. 1, pp. 51–58, 2016. J. H. Wang, S. R. Li et al., "Ten years review of screening and early diagnosis of colorectal cancer in China: 1994–2005," Gastroenterology, vol. 11, pp. 245–250, 2006. W. B. Chen and G. J. Zhu, "Efficacy and safety of FOLFOX regimen in the treatment of advanced stage colorectal cancer," Modern Medical (China), vol. 18, pp. 92-93, 2012.